Hikma launches desvenlafaxine succinate extended-release tablets in the US market

The tablets are indicated for the treatment of major depressive disorder.

West-Ward’s desvenlafaxine succinate ER tablets, 50 mg and 100 mg, are indicated for the treatment of major depressive disorder, and are in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs).

According to IMS Health, US sales of desvenlafaxine succinate ER Tablets in 50 mg and 100 mg strengths were approximately $853 million in the 12 months ending January 2017.

Mike Raya, CEO of West-Ward said: “We are pleased to be adding this product to our non-injectables portfolio in the US.  The launch demonstrates our strong R&D and regulatory capabilities and we have a large pipeline of differentiated products to drive sustainable growth for this business.”